ワイパックス錠０．５ ０．５ｍｇ
基本情報
| 項目 | 値 |
|---|---|
| DrugBank ID | DB00186 |
| エビデンスレベル | L5（計算予測のみ） |
| 予測適応症数 | 47 |
| 日本商品名（例） | ロラゼパム錠０．５ｍｇ「サワイ」, ロラゼパム錠１ｍｇ「サワイ」, ロラゼパム１ｍｇ錠 |
承認適応症（KEGG）
神経症における不安
予測適応症（TxGNN）
以下は TxGNN モデルにより予測された潜在的新適応症です。スコアが高いほど関連性が高いと予測されています。
| # | 適応症 | スコア | ソース |
|---|---|---|---|
| 1 | visual epilepsy | 99% | DL |
| 2 | trigeminal nerve neoplasm | 99% | DL |
| 3 | insomnia (disease) | 99% | DL |
| 4 | reading seizures | 99% | DL |
| 5 | orgasm-induced seizures | 99% | DL |
| 6 | thinking seizures | 99% | DL |
| 7 | micturation-induced seizures | 99% | DL |
| 8 | startle epilepsy | 99% | DL |
| 9 | audiogenic seizures | 99% | DL |
| 10 | eating seizures | 99% | DL |
| 11 | acute encephalopathy with biphasic seizures and late reduced diffusion | 99% | DL |
| 12 | trigeminal neuralgia | 99% | DL |
| 13 | sleep disorder, initiating and maintaining sleep | 99% | DL |
| 14 | attention deficit-hyperactivity disorder | 99% | DL |
| 15 | status epilepticus | 98% | DL |
| 16 | faciodigitogenital syndrome | 98% | DL |
| 17 | 14q12 microdeletion syndrome | 98% | DL |
| 18 | beta-ketothiolase deficiency | 98% | DL |
| 19 | Rett syndrome, congenital variant | 98% | DL |
| 20 | restless legs syndrome | 98% | DL |
| 21 | adolescent/adult onset autosomal dominant epilepsy with auditory features | 97% | DL |
| 22 | epilepsy with generalized tonic-clonic seizures | 97% | DL |
| 23 | epilepsy, childhood absence, susceptibility to | 97% | DL |
| 24 | chondromyxoid fibroma | 97% | DL |
| 25 | Lennox-Gastaut syndrome | 96% | DL |
| 26 | myoclonic-atonic epilepsy | 96% | DL |
| 27 | partial epilepsy | 96% | DL |
| 28 | partial motor epilepsy | 96% | DL |
| 29 | febrile infection-related epilepsy syndrome | 96% | DL |
| 30 | perioral myoclonia with absences | 96% | DL |
| 31 | cutis verticis gyrata | 95% | DL |
| 32 | trichotillomania | 95% | DL |
| 33 | atypical childhood epilepsy with centrotemporal spikes | 95% | DL |
| 34 | photosensitive occipital lobe epilepsy | 95% | DL |
| 35 | cryptogenic late-onset epileptic spasms | 95% | DL |
| 36 | attention deficit hyperactivity disorder, inattentive type | 95% | DL |
| 37 | guanidinoacetate methyltransferase deficiency | 95% | DL |
| 38 | electroclinical syndrome | 94% | DL |
| 39 | epilepsy | 94% | DL |
| 40 | specific developmental disorder | 93% | DL |
| 41 | early onset absence epilepsy | 93% | DL |
| 42 | Wernicke-Korsakoff syndrome | 92% | DL |
| 43 | alcohol withdrawal | 90% | DL |
| 44 | absence epilepsy | 85% | DL |
| 45 | early myoclonic encephalopathy | 77% | DL |
| 46 | anxiety disorder | 59% | DL |
| 47 | anxiety | 51% | DL |
免責事項
これらの予測は研究目的のみであり、医療アドバイスを構成するものではありません。 臨床応用には必ず適切な検証が必要です。